About tucatinib
HER2 tyrosine kinase inhibitor
Used for
- Used with trastuzumab and capecitabine for advanced HER2-positive breast cancer, including disease that has spread to the brain.
Usual adult dose
300 mg by mouth twice daily, with trastuzumab and capecitabine; clinicians may adjust for side effects or liver problems.
Common side effects
- Diarrhea
- Hand-foot syndrome
- Nausea and vomiting
- Raised liver enzymes
Important warnings
- Severe diarrhea can occur and may cause dehydration or kidney problems.
- Liver injury is possible; liver tests are monitored during treatment.
- Can harm an unborn baby; effective contraception is needed during treatment.
- Report severe or persistent diarrhea, yellow skin, or dark urine promptly.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong CYP3A inducers may lower tucatinib levels and reduce effectiveness.
- Strong or moderate CYP2C8 inhibitors may increase tucatinib levels.
- Tucatinib can raise levels of some medicines, including certain statins and digoxin.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.